This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Legal and regulatory update
Go to paperABSTRACT: The European Commission has launched a public consultation on its proposed amendments to the Medical De…

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

BIOTECanada and the Journal of Commercial Biotechnology have partnered to provide BIOTECanada members with free and discounted subscriptions. New BIOTECanada

Stem cells are a rapidly developing technology area. The pace of scientific and clinical progress is accompanied by new patents,

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case
Go to paperABSTRACT: …

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cell therapy: European legal and regulatory implications
Go to paperABSTRACT: This paper reviews some of the legal and regulatory considerations that may a…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Bioterrorism and bioethics: Challenges for industry, government and society
Go to paperABSTRACT: The emerging threat of bioterrorism raises important chall…

This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s

I have been struggling to understand the utility of Google Glass in most of the presented use cases. The Google Glass

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ATMP in practice: Towards a new industry landscape in tissue engineering
Go to paperABSTRACT: Regulatory divergences and market fragmentation across member…